BAUSCH

📅 Upcoming

🕒 Recent(90d)

News

• Next-gen RNAi drugmaker City prices $200M IPO
  The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver.
  biopharma_dive · 16d ago
• City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq
  City Therapeutics has gone public with an upsized $200 million IPO, on the same day that Frazier Life Sciences listed its second biotech-focused shell company.
  fiercebiotech · 16d ago
• Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits again
  Bausch + Lomb CEO Brent Saunders is making a second exit from the eye health company, as the president of parent Bausch Health steps in temporarily. Plus, Paragon Labs is buying out Apogee talent a…
  fiercebiotech · 16d ago
• Brent Saunders out as Bausch + Lomb CEO, an abrupt end to three-year run
  Brent Saunders, one of biopharma’s most prominent dealmakers and highest-paid leaders, is out as CEO of Bausch + Lomb, failing to add another multibillion-dollar company sale to his résumé. In a
  endpoints · 19d ago
• Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
  Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
  biopharma_dive · 20d ago
• ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
  ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.
  fiercebiotech · 1mo ago
• FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
  After reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to implementing significant design remediations.
  biospace · 1mo ago
• FDA warns Bausch and Lomb, Indian API maker for GMP issues
  The US Food and Drug Administration (FDA) recently issued warning letters to ophthalmic product maker Bausch and Lomb and an Indian active pharmaceutical ingredient (API) maker for violations of go…
  raps · 1mo ago
• Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
  A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
  biopharma_dive · 2mo ago
• Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail
  While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.
  biospace · 2mo ago